13 items including Jakavi receive price cuts in May

5 voluntary price adjustments

Premium pricing granted to Naratan ODT terminated with 4 same-ingredient drug listings

Lorviqua’s drug price adjusted with its reimbursement expansion, which covers ALK-positive non-small cell lung cancer

Starting May 1, the insurance price ceiling of 13 items on the drug reimbursement list will be reduced.

 

Among them, five items are voluntary reductions requested by the manufacturers.

 

According to industry sources on the 28th, the insurance ceiling prices of 13 items will be reduced in May, including the price of Jakavi Tab, which will be lowered based on the Price-Volume Agreement.

 

Jakavi Tab (ruxolitinib phosphate, Novartis), a treatment for myelofibrosis, will have its price reduced under Type B Price-Volume Agreement negotiations.

 

Type B negotiations are conducted if the maximum price was previously adjusted under Type A negotiations, or if the claims amount for the same product group has increased by more than 60% compared to the previous year's claims amount without Type A negotiations, or the increase is 10% or more and the increase amount exceeds KRW 50 billion.

 

In such cases, the price is adjusted through price negotiations with the National Health Insurance Service.

 

Accordingly, the price of Jakavi 5mg tablets will be reduced from KRW 25,962 to KRW 25,339, Jakavi 10mg tablets from KRW 38,943 to KRW 38,398, Jakavi 15mg tablets from KRW 52,199 to KRW 59,460, and Jakavi 20 mg tablets will be reduced from KRW 52,213 to KRW 50,960.

 

Lorviqua, reimbursement for which has been expanded to cover the reimbursement of first-line treatment for anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer, underwent a procedure to adjust the maximum price in accordance with the expansion of the scope of use of risk-sharing agreement drugs.

 

As a result, the price of Lorviqua Tab 25mg will be reduced from KRW 52,819 to KRW 51,234, and the price of Lorviqua Tab 100mg will be reduced from KRW 158,457 to KRW 153,703.

 

Two migraine treatment drugs that contain naratriptan, will have their prices reduced due to the expiration of the pricing premium.

 

This is because there are now four or more Naratan ODT 2.5mg products available.

 

The health authorities terminate the premium pricing immediately when the number of companies with the same formulation registered after the expiration of the premium pricing period (one year) reaches four or more.

 

As a result, the price of CMG Pharm’s Narafil ODF 2.

 

2.5mg will be reduced from KRW 2,437 to KRW 2,193, and Yuyu Pharmaceutical's Nagran ODT 2.5mg will be reduced from KRW 2,867 to KRW 2,193.

 

These products were previously granted first-generic exclusivity last month, but the premium was terminated within a month due to the introduction of same-ingredient products.

 

A total of 5 products will have their price ceiling reduced following voluntary price reduction requests from manufacturers.

 

These include 3 products from Daewoong Bio (Serotapin Tab), one from Bukwang Pharm (Ariplus Tab), and one from Hyundai Pharm (DM Duo Tab).

 

The price of Serotapin Tab 25mg will be reduced from KRW 274 to KRW 230, Serotapin Tab 100mg from KRW 688 to KRW 544, and Serotapin Tab 200mg from KRW 1,012 to KRW 927.

 

The price of Ariplus Tab will be adjusted from KRW 3,879 to KRW 2,990, and DM Duo Tab will be adjusted from KRW 3,879 to KRW 3,658.

 

Ariplus and DM Duo are donepezil + memantine combination drugs that were listed for reimbursement in March.

 

Bukwang and Hyundai voluntarily lowered their drug prices just two months after their release.